doi: 10.1111/1753-6405.13109

## Pregnancy – a key moment for engaging women with hepatitis B in care

Christine Roder,<sup>1,4</sup> Sheital Chand,<sup>2</sup> Susan Streat,<sup>1,2</sup> Sarah Beynon,<sup>1</sup> Emily Huning,<sup>3</sup> Paul Dabkowski,<sup>2</sup> Eugene Athan,<sup>1</sup> Amanda J. Wade<sup>1,4</sup>

- 1. Department of Infectious Diseases, University Hospital Geelong, Barwon Health, Victoria
- 2. Department of Gastroenterology, University Hospital Geelong, Barwon Health, Victoria
- Department of Obstetrics and Gynaecology,
   University Hospital Geelong, Barwon Health,
   Victoria
- 4. Disease Elimination, Burnet Institute, Victoria

In 2017, only 17% of Australians living with hepatitis B received appropriate monitoring, and half of those who required hepatitis B treatment received it. 1 Using current projections, Australia will not reach the 2030 World Health Organization (WHO) goal of a 65% reduction in hepatitis B mortality until 2051 – a delay of 21 years.<sup>2,3</sup> Key to achieving the WHO target is linkage to hepatitis B care. In 2013, a Victorian study demonstrated suboptimal management of hepatitis B in pregnancy.4 A review at our institution found similar results, prompting the development of a collaborative referral pathway.5 A working party from obstetrics, gastroenterology and infectious diseases departments agreed to the following intervention for women with hepatitis B: antenatal medical review, if hepatitis B virus (HBV) viral load >200,000 IU/ ml care through the high-risk obstetricianled antenatal service, referral to Liver Clinic, and education at the high-risk antenatal clinic from hepatology nurses. A Liver Clinic referral pack, containing hepatitis B patient information, pre-printed pathology slips and a referral proforma, was provided in the antenatal clinic. In 2013, the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) also recommended antenatal HBV viral load testing.<sup>6</sup> The aim of this study was to compare hepatitis B management in pregnancy and engagement in care post-partum, pre- and post-implementation of a collaborative referral pathway at University Hospital Geelong (UHG), a regional, tertiary maternity hospital in Victoria.

Pregnant women receiving care at UHG with hepatitis B (surface antigen detected) were identified via antenatal screening results or delivery records. The pre-intervention group received pregnancy care from 2008 to 2013; the post-intervention group from 2014 to 2018. The following data were collected to assess hepatitis B management during pregnancy: referral to and attendance at Liver Clinic; completion of liver function tests: HBV e antigen (eAg): HBV viral load: indication for and exposure to antiviral therapy and neonate birth dose HBV vaccine and immunoglobulin. HBV replicative status was assessed according to the contemporary RANZCOG guidelines for each group: eAg or HBV viral load pre-intervention, and HBV viral load post-intervention. Antenatal antiviral therapy was indicated at HBV viral load >200,000 IU/ml. Engagement in care post-partum was defined as attendance at Liver Clinic appointments at least annually. Pearson's chi-squared or Fisher's exact tests were used as appropriate. Analysis was undertaken using STATA/MP 16.1 (StataCorp LLC, Tx, USA). This study was approved by the Barwon Health Research Ethics Committee (19/11).

Twenty-nine women had 35 pregnancies resulting in 34 live births pre-intervention; 31 women had 36 pregnancies all resulting in live births post-intervention. The median age at delivery was 30 years (interquartile range [IQR] 25–34) pre-intervention and 30.5 years (IQR 26–32) post-intervention. The proportion of women born overseas was 19/29 (66%) pre-intervention and 28/31 (90%) post-intervention. Data and analysis for hepatitis B

management during pregnancy is presented in Table 1. HBV viral load testing was performed more frequently post-intervention 33/36 (91%) compared to pre-intervention 11/35 (31%; p<0.001).

Pre-intervention, four of 29 women (14%) attended Liver Clinic annually post-partum: one remains engaged seven years postpartum, one attended for five years and then moved out of the area, one attended for two vears and then became lost to follow-up. and one attended for two years and was discharged from the clinic. Post-intervention, 21 of 31 women (68%) attended Liver Clinic annually post-partum: 16 remain engaged in care (median duration 4 years, range 2-7), three are lost to follow-up and two moved out of the area. Women in the post-intervention group were significantly more likely to be engaged in Liver Clinic care post-partum (16/31 [52%] vs. 1/29 [3%], p<0.001).

A collaborative referral pathway has improved care for pregnant women with hepatitis B at our health service and successfully linked more than half to ongoing hepatitis B care. Previous Australian studies have assessed hepatitis B management in pregnancy and infant immunoprophylaxis, but to our knowledge, none have addressed the role antenatal care could play in linking women to ongoing hepatitis B care.<sup>7,8</sup> Most women in the study were born overseas and therefore face additional language, social and economic barriers to healthcare. Addressing these barriers by creating novel pathways to care is a step towards health service equity for this important patient group.

Variable	Pre-intervention n (%) N = 35	Post-intervention n (%) N = 36	Pearson's chi squared
Referred to Liver Clinic	13 (37%)	33 (92%)	p<0.001
Attended Liver Clinic if referred	8/13 (62%)	31/33 (94%)	p=0.006
LFT performed	29 (83%)	34 (94%)	p=0.081
HBV e Ag performed	27 (77%)	30 (83%)	p=0.512
HBV e Ag detected if test performed	2/27 (7%)	6/30 (20%)	N/A
HBV viral load performed	11 (31%)	33 (91%)	p<0.001
HBV replicative status assessed per current guidelines	28 (80%)	33 (92%)	p=0.158
HBV VL >200,000 IU/ml if test performed	1/11 (9%)	6/33 (18%)	N/A
Antiviral treatment taken if indicated	1/1 (100%)	5/6 (83%)	N/A
Number of live births	34 (97%)	36 (100%)	N/A
Birth dose HBV vaccine administered if live birth	33/34 (97%)	36 (100%)	p=0.300
HBIg administered if live birth	32/34 (94%)	36 (100%)	p = 0.336

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

The authors have stated the following conflict of interest: AW has previously received funding for investigator initiated research from AbbVie.

LFT liver function tests; HBV hepatitis B virus; Ag antigen; VL viral load; HBIg HBV human immunoglobulin

Of note, this study did not capture data of women who may have sought hepatitis B care privately, at other institutions or with their general practitioner. The serologic status of infants born to women with hepatitis B was not assessed in this study.

The introduction of a collaborative referral pathway for pregnant women with hepatitis B significantly improved the assessment of viral load during pregnancy and provided an opportunity to link women into ongoing care. The optimisation of hepatitis B prevention, monitoring and treatment is required to achieve the WHO elimination targets by 2030.

## References

- Kirby Institute. HIV, Viral Hepatitis and Sexually Transmissible Infections in Australia: Annual Surveillance Report 2018. Sydney (AUST): University of New South Wales Kirby Institute; 2018.
- Polaris Observatory. Countries on Track to Achieve WHO Elimination Targets [Internet]. Sacramento (CA): California Dental Association; 2019 [cited 2020 Apr 20]. Available from: https://cdafound.org/dashboard/ polaris/maps.html
- World Health Organization. WHO Global Hepatitis Report. Geneva (CHE): WHO; 2017.
- Giles ML, Grace R, Tai A, Michalak K, Walker SP. Prevention of mother-to-child transmission of hepatitis B virus (HBV) during pregnancy and the puerperium: current standards of care. Aust N Z J Obstet Gynaecol. 2013;53(3):231-5.
- Beynon S, Health M, Athan E, Wade AJ. Management of Hepatitis B in Pregnancy at Geelong Hospital: A retrospective review. Proceedings of the 9th Australasian Viral Hepatitis Conference; 2014 Sep 17-19; Alice Springs, AUST.
- The Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Management of Hepatitis B in Pregnancy [Internet]. East Melbourne (AUST): RANZCOG; 2016 [cited 2020 Jul 2]. Available from: https://ranzcog.edu.au/statements-guidelines2016
- Bergin H, Wood G, Walker SP, Hui L. Perinatal management of hepatitis B virus: Clinical implementation of updated Australasian management guidelines. Obstet Med. 2018;11(1):23-7.
- 8. Shen EX, Lambert SB, Malo JA, Bennett S, Sheridan SL, Vasant BR, et al. Perinatal immunoprophylaxis in babies born to hepatitis B virus-positive mothers in Queensland Australia: A data linkage study. *Vaccine*. 2019;37(22):2884-8.

Correspondence to: Dr Amanda Wade, Disease Elimination Program, Burnet Institute, 85 Commercial Rd, Melbourne, 3004; e-mail: amanda.wade@burnet.edu.au